Printer Friendly

ExThera Medical's CEO Bob Ward to Present at 'OneMedForum 2013' Next Week in San Francisco.

Presentation set for Tuesday, Jan. 8, at 2:40 p.m. PST

Click here for 12/13/12 feature story in The Sentinel, featuring the company's Seraph[TM] device designed to reduce the duration of bacteremia to prevent sepsis, a top-10 cause of death in the U.S.

BERKELEY, Calif. -- ExThera Medical announced today that its President and CEO, Bob Ward, will present ExThera Medical's opportunity at 'OneMedForum 2013.' Dr. Ward's presentation will be at The Sir Francis Drake Hotel beginning at 2:40 p.m. PST on Tuesday, Jan. 8(th).

ExThera's Seraph[TM] (Selective Removal by Apheresis) Microbind[TM] Affinity Blood Filter has received enthusiastic scientific scrutiny for its potential to bind a wide range of pathogens, toxins and pro-inflammatory cytokines to thwart bacteremia and viremia in the prevention of sepsis.

While other medical treatments of bacteremia caused by S. aureus or MRSA (Methicillin-Resistant S. Aureus) rely on antibiotics with failure rates up to 40%, the Seraph[TM] apheresis device capitalizes on the affinity of the bacteria in an infected patient's blood to attach to immobilized heparin--a natural anticoagulant, with many other biological attributes. Seraph[TM] is designed to be a biomimetic adjunct to antibiotic therapy that reduces bacterial load and duration of bacteremia while lowering levels of pro-inflammatory cytokines in a patient's blood, thereby preventing complications such as endocarditis, osteomyelitis, and sepsis.

Although presently aimed at its prevention, another critically important application of Seraph[TM] is expected to be the treatment of sepsis within intensive care units (ICU). Seraph[TM] consists of a specially designed cartridge packed with a novel bioactive polymer substrate that acts as a hemofilter. By incorporating immobilized heparin, and supplemental ligands the cartridge's high-surface-area may safely and selectively reduce pro-inflammatory cytokines such as TNF-alpha and remove many toxins and pathogens such as S. aureus including MRSA, from a patient's blood before the blood is (re)infused.

About ExThera Medical

Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood-borne diseases including bacteremia and sepsis, as well as the removal of harmful substances present in banked human blood.

CAUTION: ExThera Medical's products are for investigational use only.
COPYRIGHT 2013 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U9CA
Date:Jan 3, 2013
Previous Article:Research and Markets: Butadiene Industry Outlook in France to 2016 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and...
Next Article:Research and Markets: Uncle Maddio's Pizza Joint - Uniform Franchise Offering Circular/Franchise Disclosure Document.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters